Product
Viltolarsen
Aliases
NS-065/NCNP-01
Name
Viltepso
INN Name
viltolarsen
FDA Approved
Yes
4 clinical trials
1 organization
1 indication
1 document
Indication
Duchenne muscular dystrophyClinical trial
A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)Status: Active (not recruiting), Estimated PCD: 2032-09-01
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)Status: Completed, Estimated PCD: 2023-10-19
Clinical trial
A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With Duchenne Muscular Dystrophy (DMD) Compared to Natural History ControlsStatus: Completed, Estimated PCD: 2023-06-20
Document
DailyMed Label: ViltepsoOrganization
NS Pharma